ASTRO Journals

Send us Fan Mail
Editor-in-Chief Sue Yom hosts Associate Editor Dr. Sara Alcorn, Associate Professor, Vice Chair of Clinical Strategy, and Director of Palliative Care at the University of Minnesota; Michael Shing Fung Lee, Consultant in the Department of Radiation Oncology at National University Cancer Institute and Clinical Senior Lecturer at the National University Hospital Singapore; and Dr. Henry Wong, Clinical Research Fellow in Radiation Medicine Program at the Princess Margaret Cancer Centre. They co authored the article, “Translating Evidence to Practice: Advancing Equitable Access to Dermatologic Care for Radiation Dermatitis Worldwide.”

Send us Fan Mail
The role for radiation in the management of gastric cancer is evolving, given developments in systemic therapy.  ASTRO has released updated guidelines to provide evidence-based expert consensus on where radiation fits in the modern management of this disease.  This PRO podcast from Drs. Michael Buckstein, MD, PhD, Salma Jabbour, MD, and Christopher Anker, MD will help you navigate these guidelines and also explore some of the grey areas in gastric cancer where radiation can still make a big impact in this cancer.

Send us Fan Mail
Dr. Sue Yom, Editor in Chief, co-hosts with Section Editor Dr. Kilian Salerno, Associate Research Physician at the United States’ National Cancer Institute Radiation Oncology Branch, discussing this month’s Oncology Scan, “Proton beam radiotherapy for all children and adolescents globally: Is this a realistic and cost-effective goal?” Guests include Dr. Jeannette Parkes, Head of Radiation Oncology and Radiation Medicine at Groote Schuur Hospital at the University of Cape Town in South Africa; Dr. Natia Esiashvili, Professor in the Department of Radiation Oncology at Emory University; and Dr. Derek Tsang, Clinician Investigator at Princess Margaret Cancer Centre and Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Send us Fan Mail
Editor-in-Chief Sue Yom hosts three editors who pick highlights from the special issue! Dr. Nicholas Zaorsky is Professor in the Department of Radiation Oncology at Case Comprehensive Cancer Center and Vice Chair of Education and Director of Genitourinary Oncology at University Hospitals in Cleveland. Dr. Michelle Kim, Professor in the Department of Radiation Oncology and Co-Chair of the Cancer Center Neuro-Oncology Clinical Research Team at the University of Michigan, is the section chief for Brain and Spine at the Red Journal. Dr. Bethany Anderson, Professor at the University of Wisconsin School of Medicine and Public Health in the Department of Human Oncology and specialist in breast and gynecologic cancer treatment, is our Breast cancer section editor. 
Dr. Zaorsky’s picks are: Stereotactic Body Radiation Therapy to the Prostate With Focal Boost: Analysis of the Primary Endpoint in the DELINEATE Trial Cohort E; PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial; Two-Year Outcomes of the SPARC Phase II Trial: Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Prostate Cancer; The Kilovoltage Intrafraction Monitoring Real-Time Prostate Cancer Image Guided Radiation Therapy Technology Journey: From Clinical Trials to Your Clinic; International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy; Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial; Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney; SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial; A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma; and Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-Suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.
Dr. Kim’s picks are: Long-term Results From a Phase 1 Study of Spinal Cord Constraint Relaxation With Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients With Inoperable, Previously Unirradiated Spinal Metastases With Epidural Extension; Direct-to-Unit Stereotactic Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy for Spine Metastasis; Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial; and Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
Dr. Anderson’s picks are: A Study of Curative-approach Treatment Along With Metastasis-Directed Stereotactic Body Radiation Therapy in Bone-Only Oligometastatic Breast Cancer; Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer; and Postoperative Single-Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer With GammaPod Technology: A Phase 2 Clinical Trial.

Send us Fan Mail
Deputy Editor Dr. David Palma hosts four authors from our SBRT Clinical Trials special issue: Dr. Anand Swaminath, Associate Professor at McMaster University and supervising author of “Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial”; Dr. Kristin Karlsson, Medical Physicist at Karolinska University Hospital and first author of “Dose-Volume Predictors of Fatal Bronchopulmonary Bleeding After Stereotactic Body Radiation Therapy of Centrally Located Lung Tumors: An Analysis of the Expanded HILUS Cohort”; Dr. Alexa Dang, Radiation Oncologist at BC Cancer Vancouver and first author of “Dosimetric Outcomes for Stereotactic Radiation Therapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial”; and Dr. Fabio Arcidiacono, Radiation Oncologist at S. Maria Hospital and first author of “Five-Year Survival and Safety of SABR in Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer unfit for Concurrent Radiochemotherapy: Focus on Patterns of Local Recurrence from the START-NEW-ERA Non-randomized Phase 2 Trial.”